参考文献

[1]美国临床肿瘤学会和美国病理学会.乳腺癌雌激素、孕激素受体免疫组化检测指南[J].中华乳腺病杂志(电子版)，2011，5(3)：385.

[2]Meyer M R，Haas E，Prossnitz E R，et al.Nongenomic regulation of vascular cell function and growtn by estrogen[J].Mol Cell Endocrinol，2009，308：9-16.

[3]王涛，江泽飞.美国临床肿瘤学会和美国病理医师学院乳腺癌激素受体检测指南的临床意义[J].中华病理学杂志，2010，39(11)：721-722.

[4]《乳腺癌HER2检测指南(2009版)》编写组.乳腺癌HER2检测指南(2009版)[J].中华病理学杂志，2009，38(12)：826-840.

[5]Gong Y，Sweet W，Duh Y J，et al.Chromogenic in situ hybridization is a reliable method for detecting HER2 gene status in breast cancer：a multicenter study using conventional scoring criteria and the ASCO/CAP recommendations[J].Am J Clin Pathol，2009，131(4)：409-497.

[6]Mohammadizadeh F，Ghasemibasir H，Rajabi P，et al.Correlation of E-cadherin expression and routine immunohistochemistry panel in breast invasive ductal carcinoma[J].Cancer Biomark，2009，5(1)：1-8.(https://www.daowen.com)

[7]Tsutsui S，Ohno S，Murakami S，et al.Prognostic value of epidermal growth factor receptor(EGFR)and its relationship to the estrogen receptor status in 1029 patients with breast cancer[J].Breast Cancer Res Treat，2002，71(1)：67-75.

[8]Sutton L M，Han J S，Molberg K H，et al.Intratumoral expression level of epitdermal growth factor receptor and Cytokeratin 5/6 is significantly associated with nodal and distant metastases in patients with basal-like triple-negative breast carcinoma[J].Am J Clin Pathol，2010，134(5)：782-787.

[9]Kim H S，Yom C K，Kim H J，et al.Overexpression of P53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy[J].Breast Cancer Res Treat，2010，121(3)：777-788.

[10]Baker L，Quinlan P R，Patten N，et al.P53 mutation，deprivation and poor prognosis in primary breast cancer[J].Br J Cancer，2010，102(4)：719-726.

[11]姜大庆，赵林，龙飞等.乳腺癌新辅助化疗中Ki-67、bcl-2及AI的表达与化疗效果关系的研究[J].中国实用外科杂志，2005，25(4)：230-231.

[12]马平.TOP II、P53、Ki-67、c-erbB-2在乳腺癌组织中的表达[J].现代肿瘤医学.2011，19(8)：1545-1547.